Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "A Multicenter, Randomized, Open-Label, Three-Arm, Phase 2/3 GENERATE Study - NabP + Gem vs. Modified FOLFIRINOX or S-IROX in Metastatic or Recurrent Pancreatic Cancer"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Akihiro Ohba
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Akihiro Ohba
Login to view comments.
Click here to Login
Gastrointestinal